文献速递骨质疏松与代谢性骨病

使用慢性吸入性糖皮质激素的绝经后女性骨微结构和刚度异常

Abnormal microarchitecture and stiffness in postmenopausal women using chronic inhaled glucocorticoids.
PubMed 文献 · Osteoporos Int · 2018-06-11

这项病例对照研究对比了使用慢性吸入性糖皮质激素≥6个月的绝经后女性(n=20)与年龄和种族匹配的对照(n=60),采用HRpQCT评估桡骨和胫骨的骨微结构及有限元分析评估骨刚度。结果显示吸入性糖皮质激素使用者在容积骨密度、微结构和刚度上存在显著异常,且桡骨处最为严重。

要点

  • 使用吸入性糖皮质激素的绝经后女性桡骨和胫骨的总、皮质和松质容积骨密度均较低(均P<0.05)。
  • 桡骨处皮质厚度更薄、骨小梁数目更少、骨小梁分离度和异质性更大(均P<0.03),胫骨处异质性更大(P<0.04)。
  • 桡骨全骨刚度更低(P<0.03),胫骨全骨刚度倾向于更低(P=0.09)。

核心结论

  • 使用吸入性糖皮质激素的绝经后女性相比对照在容积骨密度、微结构和刚度上存在显著异常,且桡骨处最为严重。
  • 这些初步结果提示使用吸入性糖皮质激素的绝经后女性可能存在此前未被认识的重要骨骼缺陷。

研究设计与样本

  • 病例对照研究,比较使用吸入性糖皮质激素≥6个月的绝经后女性(n=20)与年龄和种族/民族匹配的对照(n=60)。
  • 评估指标包括DXA测定的面积骨密度、桡骨和胫骨HRpQCT测定的骨小梁和皮质容积骨密度及微结构、有限元分析测定的全骨刚度。

主要发现

  • DXA显示两组平均骨密度均在骨量减少范围,吸入性糖皮质激素使用者髋部面积骨密度更低(P<0.04)。
  • HRpQCT显示吸入性糖皮质激素使用者桡骨和胫骨的总、皮质和骨小梁容积骨密度均更低(均P<0.05)。
  • 吸入性糖皮质激素使用者桡骨皮质厚度更薄、骨小梁数目更少、骨小梁分离度和异质性更大(均P<0.03),胫骨异质性更大(P<0.04)。
  • 全骨刚度在桡骨处吸入性糖皮质激素使用者更低(P<0.03),在胫骨处倾向于更低(P=0.09)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称这些结果为初步结果,提示使用吸入性糖皮质激素的绝经后女性可能存在此前未被认识的重要骨骼缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Postmenopausal (PM) women using inhaled glucocorticoids (IGCs) had substantial abnormalities in volumetric BMD (vBMD), microarchitecture, and stiffness using high resolution peripheral computed tomography (HRpQCT) compared to age- and race-matched controls. Abnormalities were most severe at the radius. These preliminary results suggest that there may be major, heretofore unrecognized, skeletal deficits in PM women using IGCs. INTRODUCTION: While oral glucocorticoids are well recognized to have destructive skeletal effects, less is known about the effects of IGCs. The detrimental skeletal effects of IGCs may be greatest in PM women, in whom they compound negative effects of estrogen loss and aging. The goal of this study was to evaluate microarchitecture and stiffness in PM women using chronic IGCs. METHODS: This case-control study compared PM women using IGCs for ≥ 6 months (n = 20) and controls matched for age and race/ethnicity (n = 60). Skeletal parameters assessed included areal BMD (aBMD) by DXA, trabecular and cortical vBMD and microarchitecture by HRpQCT of the radius and tibia, and whole bone stiffness by finite element analysis. RESULTS: By DXA, mean values in both groups were in the osteopenic range; hip aBMD was lower in IGC users (P < 0.04). By HRpQCT, IGC users had lower total, cortical, and trabecular vBMD at both radius and tibia (all P < 0.05). IGC users had lower cortical thickness, lower trabecular number, greater trabecular separation and heterogeneity at the radius (all P < 0.03), and greater heterogeneity at the tibia (P < 0.04). Whole bone stiffness was lower in IGC users at radius (P < 0.03) and tended to be lower at the tibia (P = 0.09). CONCLUSIONS: PM women using IGCs had substantial abnormalities in vBMD, microarchitecture, and stiffness compared to controls. These abnormalities were most severe at the radius. These preliminary results suggest that there may be major, heretofore unrecognized, skeletal deficits in PM women using IGCs.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Liu Y, Dimango E, Bucovsky M, et al. Abnormal microarchitecture and stiffness in postmenopausal women using chronic inhaled glucocorticoids. Osteoporos Int. 2018. PMID: 29947865. doi:10.1007/s00198-018-4591-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。